[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anticoagulant-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anticoagulant-therapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,75,97,120,146,190,219,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642197","optimizing-anticoagulation-in-pregnancies-with-mechanical-heart-valves-100642197",false,"NCT07658989","Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves","A Prospective Multicenter Cohort Pilot Study Comparing Antithrombotic Regimens in Pregnancies With Mechanical Heart Valves","Inclusion Criteria:\n\n1. Pregnant individuals with one or more MHVs\n2. Who consent to participate\n3. Are 18 years or older and\n4. Less than 12 weeks gestation\n\nExclusion Criteria:\n\n1. Have a platelet count less than 50 x 10(9)\u002FL as there is an increased risk of bleeding with thrombocytopenia, and\u002For\n2. Have active bleeding defined as bleeding resulting in a hemoglobin reduction ≥10 g\u002FL or in hemodynamic instability.\n3. Have new valve thrombosis identified immediately prior to pregnancy","FEMALE","18 Years","45 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and low dose aspirin (LDA) is comparable to warfarin\u002Fvitamin K antagonist (VKA) to reduce the chance of clotting around the mechanical valve and improve survival. The study is a pilot study as the study investigators need to ensure that the blood levels needed for adequate amounts of LMWH and warfarin can be maintained during pregnancy to be able to compare LMWH and aspirin to warfarin. If this study shows that we can collect the tests that are needed for a larger study, the individuals' information who participated in this pilot study will be moved to the larger study. The larger study will compare survival, clot development and cardiac function as well as safety of these two common blood thinners.",[27,28,29],"Pregnancy","Prosthetic Heart Valve","Anticoagulant Therapy",[27,31,32,33,34,35],"Prosthetic heart valve","Anticoagulant therapy","Low molecular weight heparin","warfarin","vitamin K antagonist","RECRUITING","2026-06-15",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2026-05-26",{"date":44,"type":21},"2030-12",{"name":46,"class":47},"Mount Sinai Hospital, Canada","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100640764","direct-oral-novel-anticoagulants-for-patients-with-high-risk-gastroesophageal-variceal-bleeding-and-portal-vein-thrombosis-100640764","NCT07602062","Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Inclusion Criteria:\n\n* Clinical and imaging diagnosis of liver cirrhosis and esophagogastric varices, with at least one previous episode of esophagogastric variceal bleeding\n* Combined with portal vein thrombosis and D-dimer \\> 0.8mg\u002FL\n* Endoscopic evaluation reveals a high risk of variceal bleeding, and endoscopic treatment is performed to prevent rebleeding of esophagogastric varices\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Received other antithrombotic therapies before (including warfarin, aspirin, low-molecular-weight heparin, etc.)\n* Combined with hepatocellular carcinoma or other malignancy\n* Combined with portal cavernoma\n* Combined with severe life-threatening diseases of circulatory, hematological and respiratory system\n* Combined with diseases requiring anticoagulant therapy, such as acute portal vein thrombosis, atrial fibrillation, lower extremity venous thrombosis, and pulmonary embolism\n* Received TIPS or liver transplantation or splenectomy\n* With contraindications to anticoagulant therapy (uncontrollable active bleeding, severe hepatic insufficiency, renal insufficiency, etc.)\n* Currently taking immunosuppressive agents, or medications that affect cytochrome P450 (including azole antifungals and protease inhibitors), or strong inducers of CYP3A4 (including rifampicin, phenytoin, carbamazepine, etc.)","ALL","75 Years",{"count":59,"type":21},175,[24],"This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis, through a prospective, multicenter, randomized controlled clinical trial, starting 48 hours after endoscopic treatment to prevent rebleeding.",[63,29,64],"Portal Vein Thrombosis","Variceal Bleeding","NOT_YET_RECRUITING","2026-05-16",{"date":68,"type":40},"2026-05-22",{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2027-12-31",{"name":74,"class":47},"Shanghai Zhongshan Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":48},"100632590","phase-4-vitamin-k-for-perioperative-warfarin-management-100632590","NCT07515664","Vitamin K for Perioperative Warfarin Management","Vitamin K Reversal of INR for Perioperative Management of Warfarin: : A Pilot Study to Assess Feasibility","Inclusion Criteria:\n\n* Warfarin therapy for ≥3 months\n* Use of home INR testing equipment\n* Scheduled for a surgical procedure that requires INR ≤ 1.5 (typically achieved with warfarin interruption)\n* INR ≤ 4 on day 7-10 prior to procedure\n\nExclusion Criteria:\n\n* Surgical procedure does not require INR ≤1.5 (typically achieved with warfarin interruption)\n* Surgical procedure with a high risk of bleeding or complications (urologic procedures, bronchoscopy, epidural injections, nerve blocks, spinal surgery)\n* Warfarin therapy for \\\u003C 3 months\n* Lack of English language proficiency\n* Use of a Heartmate II or HVAD left ventricular assist device\n* Recent thrombotic event (within 3 months)\n* CHA2DS2-VASc score \\>6\n* INR \\>4 on day 7-10 prior to procedure\n* Hypersensitivity to any component of Vitamin K or simple syrup (used in the compounding process)",{"count":83,"type":21},20,[85],"PHASE4","This is a feasibility study of uninterrupted warfarin with a one time dose of Vitamin K before a surgical procedure.",[29],"2026-04-06",{"date":90,"type":40},"2026-04-13",{"date":92,"type":40},"2025-07-03",{"date":94,"type":21},"2026-08",{"name":96,"class":47},"University of Michigan",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100622402","phase-4-bivalirudin-versus-heparin-during-pci-in-high-bleeding-risk-patients-with-acute-coronary-syndromes-100622402","NCT07383155","Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes","BRIGHT-HBR","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical evidence of NSTE-ACS or recent stabilized STEMI (≥48 hours after symptom onset) undergoing PCI\n* The patient meets the ARC criteria for HBR (≥1 major criterion or ≥2 minor criteria)\n* The patient or legal representative has been fully informed and written informed consent has been obtained\n\nExclusion Criteria:\n\n* STEMI patients within 48 hours of symptom onset\n* CABG or PCI within the prior 6 months, including for the present clinical syndrome\n* Cardiogenic shock\n* Coronary artery disease unsuitable for revascularization or requiring CABG\n* Confirmed or suspected aortic dissection\n* Treatment with a glycoprotein IIb\u002FIIIa inhibitor within 2 hours prior to the PCI (use of intravenous heparin prior to or at the time of randomization is acceptable)\n* Allergy to UFH, bivalirudin, aspirin, clopidogrel, ticagrelor, or contrast agents that cannot be adequately pre-medicated, or any prior anaphylaxis to these agents\n* Any non-cardiac conditions with an expected life expectancy of ≤12 months\n* Patients deemed by the investigator to be clinically unsuitable for coronary angiography and PCI, or who are unlikely to be able to comply with the protocol requirements, including medication adherence and follow-up visits",{"count":105,"type":21},5270,[85],"Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.\n\nMethods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-segment elevation myocardial infarction (STEMI, ≥48 hours after symptom onset) will be randomized 1:1 to bivalirudin or UFH at 70 sites in China. HBR is defined by the Academic Research Consortium (ARC)-HBR criteria. The primary composite endpoint is net adverse clinical events (NACE) at 30 days, the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding, and the major secondary endpoint is BARC types 2, 3 or 5 bleeding. The study is powered to demonstrate that bivalirudin is superior to UFH monotherapy for NACE in ACS patients with HRB at 30 days after PCI.\n\nConclusions. The BRIGHT-HBR randomized trial aims to provide evidence on whether bivalirudin reduces the incidence of NACE and clinically relevant bleeding compared with UFH monotherapy in patients with ACS who are at HBR undergoing PCI.",[109,110,111,29],"Percutaneous Coronary Intervention","High Bleeding Risk","Acute Coronary Syndromes","2026-02-01",{"date":114,"type":40},"2026-02-03",{"date":112,"type":21},{"date":117,"type":21},"2028-12-31",{"name":119,"class":47},"Shenyang Northern Hospital",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":48},"100620690","atrial-fibrillation-trial-of-left-atrial-appendage-closure-using-seralene-hemostatic-suture-100620690","NCT07360899","Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture","Left Atrial Appendage Closure During Cardiac Surgery in Atrial Fibrillation Patients With Seralene","ATRI-LASH","Inclusion Criteria:\n\nAge 18 years or older\n\nDocumented atrial fibrillation (any type)\n\nCHA₂DS₂-VASc score of 2 or greater, or equivalent stroke risk\n\nScheduled to undergo cardiac surgery (including coronary artery bypass grafting, valve surgery, or other structural cardiac surgery)\n\nAbility to understand the study and provide written informed consent\n\nExclusion Criteria:\n\nContraindication to left atrial appendage closure (e.g., presence of left atrial appendage thrombus or unsuitable anatomy)\n\nLife expectancy less than 3 months, based on clinical judgment\n\nCurrent participation in another clinical study that could interfere with the outcomes of this study\n\nActive or suspected infective endocarditis",{"count":129,"type":21},200,[24],"Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage. If a blood clot travels from the heart to the brain, it can cause a stroke.\n\nBlood-thinning medications are commonly prescribed to reduce the risk of stroke in patients with atrial fibrillation. However, some patients cannot take these medications long-term because of bleeding risk, side effects, or other medical reasons.\n\nClosing the left atrial appendage is an alternative approach to reduce the risk of stroke by preventing blood from collecting in this area. When patients undergo cardiac surgery for another indication, closure of the left atrial appendage can be performed during the same operation.\n\nThis study is designed to evaluate the safety and effectiveness of surgical closure of the left atrial appendage using a device called AtriLASH during cardiac surgery. AtriLASH is a surgical suture-based device intended to close the left atrial appendage.\n\nThe study will assess whether the left atrial appendage can be safely and effectively closed using this method in patients with atrial fibrillation undergoing cardiac surgery. The information obtained from this study may help determine whether this approach can reduce the risk of stroke and potentially decrease the need for long-term use of blood-thinning medications in selected patients.",[133,134,135,136,29],"ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION","Atrial Fibrillation (AF)","Mitral Valve Surgery","Stroke (in Patients With Atrial Fibrillation)","2026-01-14",{"date":139,"type":40},"2026-01-22",{"date":141,"type":40},"2025-12-01",{"date":143,"type":21},"2026-06-30",{"name":145,"class":47},"Institute of Cardiovascular Diseases, Vojvodina",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":158,"conditions":159,"keywords":167,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100583572","phase-3-thrombolysis-in-factor-xa-inhibitors-trial-100583572","NCT06878066","Thrombolysis in Factor Xa-inhibitors Trial","The Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With Recent Ingestion of Factor Xa-inhibitors Trial (SIFT)","SIFT","Inclusion Criteria:\n\n1. Participant must be 18 years of age or older.\n2. Ingestion of FXa inhibitors within the last 48 hours of symptom onset (or ongoing prescription of FXa inhibitor if unknown)\n3. Clinical diagnosis of AIS with disabling neurological deficit\n4. Presenting within 4.5 h of symptom onset or after awakening with symptoms of AIS with FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist.\n5. Informed consent\n\nExclusion Criteria:\n\n1. Endovascular treatment eligible patients with isolated large vessel occlusion of the intracranial internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or both confirmed by CT or MR angiography and expected time from randomization to groin puncture of \\\u003C30 minutes.\n2. Systolic BP \\>185 mmHg or diastolic BP \\>110 mmHg despite antihypertensive treatment.\n3. Known bleeding diathesis; manifest or recent severe bleeding; significant bleeding disorder last 6 months.\n4. Arterial puncture at a non-compressible site; biopsy or lumbar puncture \\\u003C7 days; major surgery, traumatic external heart massage, obstetrical delivery or serious trauma \\\u003C14 days; history of intracranial haemorrhage; stroke \\\u003C2 months, CNS neurosurgery \\\u003C2 months; serious head trauma \\\u003C2 months; pericarditis; sepsis; bacterial endocarditis; pericarditis; acute pancreatitis; neoplasm with increased bleeding risk; any serious medical illness likely to interact with treatment (i.e. aortic dissection); confounding pre-existent neurological or psychiatric disease.\n5. Any condition that, in the opinion of the treating physician, puts a patient at risk if treated with thrombolysis (i.e. signs of cerebral hemorrhage, known cerebral amyloid angiopathy, CT with signs of early ischemia greater than one-third of the middle cerebral artery territory).\n\n   Prior\u002FConcomitant Therapy\n6. Use of a) direct thrombin (II) inhibitor (Dabigatran) or b) warfarin with an INR ≥1.8; c) heparin \\\u003C48 h; d) treatment dose of LMWH \\\u003C24 h.\n\n   Prior\u002FConcurrent Clinical Study Experience\n7. Hypersensitivity to Alteplase or Tenecteplase",{"count":155,"type":21},300,[157],"PHASE3","This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain.\n\nHowever, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group.\n\nThe SIFT trial will compare two groups of stroke patients who take FXa inhibitors:\n\nOne group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care.\n\nRight now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT.\n\nMore and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.",[160,136,161,162,29,163,164,165,166],"Stroke","Ischemic Stroke","Acute Ischemic Stroke","Factor Xa Inhibitor","Intracranial Hemorrhages","Hemorrhagic Transformation Due to Acute Stroke","Bleeding in the Brain",[168,162,161,169,170,171,172,173,174,175,176,160,177,178,179],"Thrombolysis","Factor Xa Inhibitors","Atrial Fibrillation-Related Stroke","Intravenous Thrombolysis","Tissue Plasminogen Activator","Tenecteplase","Alteplase","Symptomatic Intracranial Hemorrhage","SIFT Trial","Acute stroke","Direct Oral Anticoagulants","DOACs","2025-08-29",{"date":182,"type":40},"2025-09-02",{"date":184,"type":40},"2025-03-14",{"date":186,"type":21},"2037-12-31",{"name":188,"class":47},"Guri Hagberg",13,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":48},"100588922","safety-and-efficacy-of-edoxaban-and-rivaroxaban-to-cerebral-venous-thrombosis-in-chinese-patients-100588922","NCT06947707","Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients","Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Patient aged from 18 to 80 years and no gender preference;\n2. Diagnosis of CVT as confirmed on MRBTI\u002FMRV or CT\u002FCTV or DSA;\n3. Acute or subacute CVT from onset to door within 4 weeks;\n4. The treating clinician irrelevant to the study is of the opinion that the patient is appropriate for edoxaban or rivaroxaban;\n5. Patient or legally authorized representative is able to give written informed consent.\n\nExclusion Criteria:\n\n1. Patient refuse to take edoxaban or rivaroxaban to treat CVT;\n2. Pregnancy or breastfeeding women at the time of enrollment, or women who plan to get pregnant during study;\n3. Patient is anticipated to require invasive procedure (e.g. thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation;\n4. CVT secondary to central nervous system infection or severe head trauma;\n5. It is in the proliferative stage of malignant tumors currently or within 6 months of diagnosis;\n6. Bleeding diathesis or other contraindication to anticoagulation;\n7. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use;\n8. Concomitant use of strong CYP3A4 or P-gp inhibitors;\n9. Impaired renal function (CrCl\\\u003C30 mL\u002Fmin using Cockcroft-Gault equation) or investigator anticipate the CrCl lower than 30 mL\u002Fmin during study;\n10. Impaired liver function (ALT or AST exceeds twice the normal upper limit) or diagnosed as acute hepatitis currently;\n11. Patient is unable to swallow due to depressed level of consciousness or other reasons;\n12. Patient has a severe or fatal comorbid illness with life expectancy less than 6 months;\n13. Patient with severe hypertension (SBP≥180mmHg and\u002For DBP≥110mmHg);\n14. Patient is known to be allergic to edoxaban or rivaroxaban.","80 Years",{"count":199,"type":21},1486,"OBSERVATIONAL","The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous thrombosis (CVT). The main question it aims to answer are:\n\n* Do cerebral veins or venous sinuses recanalize during the treatment period of edoxaban and rivaroxaban?\n* Do the bleeding events occur during the treatment period of edoxaban and rivaroxaban?\n\nThe main tasks participants will be asked to do:\n\n* Participants will comply fully with the prescribed regimen and take the edoxaban or rivaroxaban as directed at the specified dosage.\n* Participants will return to hospital for scheduled follow-up assessments at months 3, 6, 9, and 12 post-enrollment to undergo face-to-face visits with investigators.",[203,204,205,29,206,207,208,209,210],"Cerebral Venous Thrombosis","Anticoagulants and Thrombotic Disorders","Anticoagulation Treatment","Anticoagulant Drugs","NOACs","Anticoagulant Prophylaxis\u002FTherapy","Anticoagulation With NOAC","Anticoagulation With Direct Oral Anticoagulants","2025-04-20",{"date":213,"type":40},"2025-04-27",{"date":215,"type":40},"2025-04-10",{"date":72,"type":21},{"name":218,"class":47},"Xuanwu Hospital, Beijing",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":48},"100569304","adverse-drug-events-in-patients-on-oral-anticoagulation-in-the-emergency-department-100569304","NCT06692504","Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department","Real-life Epidemiology of Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department Setting","ADEOA","Inclusion Criteria:\n\n* Age ≥18 years\n* Admission to adult emergency department of Besançon University Hospital\n* Study period: January 1, 2018 to December 31, 2019\n* Current oral anticoagulation therapy with:\n\n  * Acenocoumarol\n  * Apixaban\n  * Dabigatran\n  * Fluindione\n  * Rivaroxaban\n  * Warfarin\n\nExclusion Criterion:\n\n\\- Discontinuation of anticoagulant therapy for more than 24 hours",{"count":228,"type":21},2080,"Rationale:\n\nAccording to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004, 31% in 2009). The EMIR study (2007) showed that VKAs were the leading cause of hospitalization for adverse effects (12.3%), with approximately 5,000 fatal hemorrhage-related accidents annually. Treatment and prevention of thromboembolic events represent a major public health challenge due to increased mortality, severity of functional sequelae, growing number of patients requiring treatment, and medical, social, and economic consequences. In 2013, an estimated 3.12 million patients received anticoagulation (4-5% of the French population). Several types of adverse events under oral anticoagulation appear to have high incidence in emergency settings: traumatic hemorrhage, spontaneous hemorrhage, asymptomatic overdose, and thrombosis. Different variables are associated with these events in patients admitted to emergency departments under oral anticoagulant treatment, but few studies have been conducted in real-world settings with large patient samples.\n\nHypothesis:\n\nIatrogenic events have a high incidence in patients admitted to emergency departments under oral anticoagulants and are a factor in early and late morbidity and mortality.\n\nPrimary Objective:\n\nTo describe the characteristics of patients admitted to the emergency department on oral anticoagulant therapy, with a particular focus on characterizing those presenting with Adverse Drug Events (ADEOA).\n\nStudy Design:\n\n* Type: Observational, descriptive study\n* Duration: 36 months total (24 months for data collection, 12 months for analysis)\n* Sample Size: Estimated 2,080 patients (approximately 20 patients\u002Fweek over 2 years)\n\nInclusion Criteria:\n\n* Age ≥18 years\n* Admission to adult emergency department\n* Study period: January 1, 2018 to December 31, 2019\n* Current oral anticoagulation therapy with:\n\n  * Acenocoumarol (Sintrom®\u002FMinisintrom®)\n  * Apixaban (Eliquis®)\n  * Dabigatran (Pradaxa®)\n  * Fluindione (Previscan®)\n  * Rivaroxaban (Xarelto®)\n  * Warfarin (Coumadine®)\n\nExclusion Criterion:\n\n\\- Discontinuation of anticoagulant therapy for more than 24 hours\n\nPrimary Outcome Measures:\n\n1. Description of oral anticoagulant groups based on medication type\n2. Characterization of Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department (ADEOA):\n\n   1. Presence of ADEOA:\n\n      * Traumatic hemorrhage: acute bleeding following recent trauma\n      * Spontaneous hemorrhage: acute bleeding unrelated to recent trauma\n      * Asymptomatic overdose: INR \\>3 for vitamin K antagonist patients\n      * Thrombosis: new arterial or venous thrombosis despite ongoing anticoagulation\n   2. Absence of ADEOA\n\nSecondary Outcome Measures:\n\n1. Assessment of adherence to oral anticoagulant prescribing guidelines\n2. Identification of etiological factors for anticoagulation-related adverse events\n3. Identification of early morbidity and mortality risk factors\n4. Evaluation of medical-economic impact of adverse events and cost-effectiveness analysis of adverse events\n5. Quality of life assessment",[231,232,29,233],"Hemorrhage","Thrombosis","Traumatic Hemorrhage",[235,236,237,238,239,240,241,242,232,243,244],"anticoagulant therapy","oral anticoagulant","emergency department","emergency medicine","hemorrhage","Traumatic hemorrhage","Spontaneous hemorrhage","Asymptomatic overdose","epidemiology","mortality","2024-11-14",{"date":247,"type":40},"2024-11-18",{"date":249,"type":40},"2021-01-01",{"date":251,"type":21},"2025-09",{"name":253,"class":47},"Centre Hospitalier Universitaire de Besancon",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":48},"100565653","monitoring-bleeding-of-patients-using-noac-anticoagulation-therapy-in-proximal-femoral-fracture-internal-fixation-surgery-without-waiting-we-measure-bleeding-in-surgery-and-the-levels-of-noac-drug-in-blood-we-will-try-to-compare-to-regular-pateints-later-100565653","NCT06644976","Monitoring Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery Without Waiting. We Measure Bleeding in Surgery and the Levels of Noac Drug in Blood. We Will Try to Compare to Regular Pateints Later","Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery","Inclusion Criteria:\n\nabove 18 y.o femoral neck fracture NOAC capable of making inform consent primary surgery\n\n\\-\n\nExclusion Criteria:\n\n* under 18 y.o\n* anti platelet therapy (aspirin is not included)\n* creatinine clearance under 50\n* active anti cancer therapy\n* ITP patients\n* non capable of making inform consent\n* patients which decide not to proceed with the expeirment",{"count":20,"type":21},"until today we waited at least 24 hours before surgery of femoral neck fractures in patients who take anticouagolation . in our new reasearch we belive that patients who take NOAC can go under surgery earlier with minimal risk",[264,265,29],"Osteoperosis","Femoral Neck Fractures","2024-10-14",{"date":268,"type":40},"2024-10-16",{"date":270,"type":40},"2024-08-20",{"date":272,"type":21},"2025-12",{"name":274,"class":47},"Meir Hospital, Kfar Saba, Israel"]